3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Breast Neoplasms
285
Lymphoma
201
Lymphoma, Large B-Cell, Diffuse
167
Sarcoma
141
Precursor Cell Lymphoblastic Leukemia-Lymphoma
109
Hodgkin Disease
85
Lymphoma, Non-Hodgkin
78
Burkitt Lymphoma
67
Lymphoma, Follicular
61
Leukemia
58
Ovarian Neoplasms
50
Neoplasms
50
Triple Negative Breast Neoplasms
49
Lymphoma, Mantle-Cell
48
Multiple Myeloma
47
Neuroblastoma
44
Carcinoma, Hepatocellular
44
Neoplasm Metastasis
41
Lymphoma, B-Cell
33
Lymphoma, Large-Cell, Anaplastic
31
Lymphoma, T-Cell, Peripheral
27
Recurrence
26
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
25
Osteosarcoma
25
Liposarcoma
25
Leiomyosarcoma
25
Urinary Bladder Neoplasms
23
Lymphoma, Large-Cell, Immunoblastic
23
Liver Neoplasms
22
Endometrial Neoplasms
21
Interventions
tazemetostat
1
relatlimab
1
regorafenib
1
durvalumab
1
brigimadlin
1
bintrafusp alfa protein, human
1
Nivolumab
1
Doxorubicin
1
Clinical Trials, Phase II as Topic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Tertiary Lymphoid Structures
×
Doxorubicin
×
Clear all
NCT04874311
2025-08-13
TRUST
Institut Bergonié
Phase 2
Recruiting
80 enrolled